Treatment Duration in Patients With Transplant-Ineligible NDMM
Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.
EP: 1.Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center
EP: 2.Transplant-Eligible NDMM: Overview of Available Induction Therapies
EP: 3.Selection of Induction Therapy in Patients With Transplant-Eligible NDMM
EP: 4.Patient Profile 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 5.Selecting First-Line Therapy for Patients With Transplant-Ineligible NDMM
EP: 6.Transplant-Ineligible NDMM: Optimizing Therapy for Frailer Patients
Now Viewing
EP: 7.Treatment Duration in Patients With Transplant-Ineligible NDMM
EP: 8.Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 9.Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options
EP: 10.Sequencing Therapies in Relapsed/Refractory Multiple Myeloma
EP: 11.Bispecifics in the Treatment of Multiple Myeloma: Teclistamab
EP: 12.BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma
EP: 13.Non-BCMA Targeting Therapies in Multiple Myeloma
EP: 14.Experts Discuss SOC for Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 15.Bispecifics-Based Combination Therapy in Multiple Myeloma
EP: 16.CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 17.Patient Profile 3: Patient With MM Progressing After Several Prior Therapies
EP: 18.Multiple Myeloma: Unmet Needs and Future Perspectives
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
